Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Clostridium Difficile (C. Difficile) Clear all
Completed Phase 4 Interventional Results available

Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin

NCT01818141
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Vancomycin, Fidaxomicin
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jul 21, 2026, 5:29 PM EDT
Terminated Phase 4 Interventional

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

NCT03200093
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Oral Vancomycin, Placebo
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jul 21, 2026, 5:29 PM EDT
Completed No phase listed Observational

C.Difficile Observational Study

NCT06277999
View directory record Official record
Conditions
Clostridium Infections
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Sacramento, California • Hamden, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of a Single Dose of CRS3123

NCT01551004
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
CRS3123, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Jul 21, 2026, 5:29 PM EDT
Enrolling by invitation Phase 1 Interventional

Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea

NCT01868373
View directory record Official record
Conditions
Active C. Difficile Colitis
Interventions
Microbiota Transplantation (FMT)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2036
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Jul 21, 2026, 5:29 PM EDT
Completed No phase listed Observational

Protocol for Admission Toxigenic C. Difficile Surveillance

NCT04014608
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Standard Practice to Prevent Hospital Onset CDI
Other
Lead sponsor
Endeavor Health
Other
Eligibility
Up to 1 Year
Enrollment
148,549 participants
Timeline
2016 – 2018
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Jul 21, 2026, 5:29 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

NCT05606159
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Bacillus velezensis DSM 33864, Placebo
Dietary Supplement
Lead sponsor
Novozymes A/S
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 21, 2026, 5:29 PM EDT
Completed No phase listed Observational

Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics

NCT03117582
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Stool specimen
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jul 21, 2026, 5:29 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease

NCT02076438
View directory record Official record
Conditions
Diarrhea
Interventions
Probiotics
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Jul 21, 2026, 5:29 PM EDT
Terminated Phase 4 Interventional Results available

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

NCT04626947
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
Interventions
Bezlotoxumab
Biological
Lead sponsor
David Binion, MD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

NCT02589847
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
RBX2660, Standard of Care Antibiotics
Biological · Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

NCT00106509
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis
Interventions
tolevamer potassium-sodium (GT267-004)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
99
States / cities
Phoenix, Arizona • Rogers, Arkansas • Burbank, California + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Jul 21, 2026, 5:29 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Fecal Transplant for Relapsing C. Difficile Infection

NCT01703494
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Fecal Microbiota Transplantation, Sham Fecal Microbiota Transplantation
Biological
Lead sponsor
Colleen Kelly
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
The Bronx, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Jul 21, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional

Stool Transplants to Treat Refractory Clostridium Difficile Colitis

NCT02127398
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
fecal microbiota
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 21, 2026, 5:29 PM EDT
Terminated Phase 3 Interventional Results available

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

NCT04802837
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ridinilazole, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
12 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 21, 2026, 5:29 PM EDT
Terminated Phase 3 Interventional

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

NCT00466635
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous, Diarrhea, Clostridium Difficile
Interventions
GT267-004 (tolevamer potassium sodium)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Modesto, California • Honolulu, Hawaii • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Jul 21, 2026, 5:29 PM EDT
Terminated Phase 4 Interventional Results available

IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff

NCT00177970
View directory record Official record
Conditions
Clostridium Difficile-associated Diarrhea (CDAD)
Interventions
intravenous immunoglobulin G (IVIG), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

NCT00350298
View directory record Official record
Conditions
Clostridium Infections
Interventions
GS-CDA1/MDX-1388, normal saline
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Los Angeles, California • Oakland, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Jul 21, 2026, 5:29 PM EDT
Terminated Phase 4 Interventional Results available

Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.

NCT03937999
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Bezlotoxumab
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
60 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

NCT03244644
View directory record Official record
Conditions
Clostridium Difficile Infection (CDI)
Interventions
RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
60
States / cities
Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 2 Interventional

A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea

NCT00034294
View directory record Official record
Conditions
Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis, Clostridium Difficile Diarrhea, Antibiotic-associated Colitis, Antibiotic-associated Diarrhea
Interventions
GT160-246
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
58
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

NCT02299570
View directory record Official record
Conditions
Enterocolitis Clostridium Difficile Recurrent
Interventions
RBX2660 (microbiota suspension), Placebo
Biological · Other
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

NCT03595553
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ridinilazole, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
49
States / cities
Birmingham, Alabama • Sun City, Arizona • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

NCT03931941
View directory record Official record
Conditions
Clostridium Difficile Infection, Infection, Communicable Diseases
Interventions
RBX2660
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
46
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jul 21, 2026, 5:29 PM EDT